IGI Laboratories, Inc., a NJ-based specialty generics company, has acquired the regulatory rights to 18 drug products from AstraZeneca, 17 of which are marketed and include 17 injectable products and 1 suppository product. All of the products had been approved by the FDA as ANDAs or NDAs prior to their discontinuation or withdrawal from the market. According to IMS Health, the current market in the U.S. for the therapeutic areas the products are indicated for, is estimated at $200 million as of ...